CAR-T news — June 2017

“One of the leading CAR T-cells immunotherapy company, Cellectis dosed the first blood cancer patient with the allogeneic, “off-the-shelf” CAR-T therapy, UCART123 at Weill Cornell Medicine and NewYork-Presbyterian Hospital…”

Scientists Get Closer to First CAR T-Cells Based Immunotherapy for Humans

Cellectis’ off-the-shelf CAR-T Cancer Therapy has Entered the Clinic

Cellectis’ Press Release…

First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital | Cellectis


A journalist from Bloomberg News is working on a story similar to the one below:

For experimental cancer therapy, a struggle to ensure supply keeps up with demand | Science | AAAS


“The sky-high cost of producing CAR T cells, and limitations on the availability and regulatory qualification of reagents can be barriers to making CAR T cell therapy accessible…”

Biotechin.Asia- Driving CAR T-Cell Therapy From Bench to Bedside

CAR-T Value Calculation In The Firing Line | Seeking Alpha


Work continues on applying CAR-T to solid tumors:

Unleashing CAR-T Therapies on Solid Tumors: Are We There Yet? | BIOtechNow

Buy Celyad And Get In On The CAR-T Space In Solid Tumors: Medicine’s Next Frontier – Celyad (NASDAQ:CYAD) | Seeking Alpha


A history of all reported deaths (clinically described as a “Grade 5 Adverse Event”) thus far from CAR-T:

EP Vantage – Spotlight – Putting a number on CAR-T deaths


Neurotoxicity needs separate treatment from CRS in CAR T-cell therapy  | (Free registration required)


Engineering CAR-T cells


CAR-T coverage in PC Magazine(!)

How Scientists Are Hacking Cancer | News & Opinion | PCMag.com

Advertisements

4 thoughts on “CAR-T news — June 2017

  1. I wonder whether patients receiving off-the-shelf UCART123 will experience graft-vs-host-disease (GVHD) which is common in transplants?

    Like

  2. I was wondering about that as well. Perhaps it’s less of an issue with a donor’s T cells than with stem cells? I haven’t yet had any issues with blood or IgIV infusions.

    Like

    • Yes, but your CAR-T was made from your own T-cells so GVHD was a non-issue. It may be an issue using T-cells from another person, right???

      Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s